Innate Pharma SA
PAR:IPH
Innate Pharma SA
Other Items
Innate Pharma SA
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innate Pharma SA
PAR:IPH
|
Other Items
€15.4m
|
CAGR 3-Years
253%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
27%
|
|
|
Valneva SE
PAR:VLA
|
Other Items
€3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Items
-€241k
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
25%
|
|
|
Inventiva SA
PAR:IVA
|
Other Items
-€24.6m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other Items
$584k
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Other Items
€3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
Innate Pharma SA
Glance View
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
See Also
What is Innate Pharma SA's Other Items?
Other Items
15.4m
EUR
Based on the financial report for Jun 30, 2025, Innate Pharma SA's Other Items amounts to 15.4m EUR.
What is Innate Pharma SA's Other Items growth rate?
Other Items CAGR 10Y
27%
Over the last year, the Other Items growth was -36%. The average annual Other Items growth rates for Innate Pharma SA have been 253% over the past three years , and 27% over the past ten years .
